Tuning acetylated chromatin with HAT inhibitors: A novel tool for therapy

Epigenetics

Volumn 5, Issue 2, 2010, Pages 105-111

  Vernarecci, Stefano ^a   Tosi, Federica ^a   Filetici, Patrizia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acetylation; Chromatin; HAT inhibitors; Yeast

Indexed keywords

MICRORNA; ENZYME INHIBITOR; HISTONE ACETYLTRANSFERASE;

ARTICLE; BIOGENESIS; NEOPLASM; SIGNAL TRANSDUCTION; ACETYLATION; ANIMAL; CHEMISTRY; CHROMATIN; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPISTASIS; GENETICS; HUMAN; METABOLISM; SACCHAROMYCES CEREVISIAE;

ACETYLATION; ANIMALS; CHROMATIN; ENZYME INHIBITORS; EPISTASIS, GENETIC; HISTONE ACETYLTRANSFERASES; HUMANS; NEOPLASMS; SACCHAROMYCES CEREVISIAE;

EID: 77953996284     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.5.2.10942     Document Type: Article

References (60)

1. Mellor J. Dynamic nucleosomes and gene transcription. Trends Genet 2006; 22:320-9.
2. Jenewein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80.
3. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, et al. New nomenclature for chromatin-modifying enzymes. Cell 2007; 131:633-6.
4. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37:391-400.
5. Esteller M. Epigentetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007; 16:50-9.
6. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Nat Rev Drug Discov 2006; 5:37-50.
7. Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer 2009; 115:5746-51.
8. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20:1293-302.
9. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001; 70:81-120. Review.
10. Howe L, Auston D, Grant P, John S, Cook RG, Workman JL, Pillus L. Histone H3 specific acetyltransferases are essential for cell cycle progression. Genes Dev 2001; 1:15.
11. Ha GH, Kim HS, Lee CG, Park HY, Kim EJ, Shin HJ, et al. Mitotic catastrophe is the predominant response to histone acetyltransferase depletion. Cell Death Differ 2009; 16:483-97.
12. Morrison AJ, Shen X. Chromatin modification in DNA repair. Results Probl Cell Differ 2006; 41:109-25.
13. Murr R, Loizou JI, Yang YG, Cuenin C, Li H, Wang ZQ, Herceg Z. Histone acetylation by Trapp-Tip60 modulates loading of repair proteins and repair fo DNA double-strand breaks. Nat Cell Biol 2006; 8:91-9.
14. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, Allis CD. Tetrahymena Histone Acetyltransferase A: a transcriptional co-activator linking gene expression to hystone acetylation. Cell 1996; 84:843-51.
15. Liu X, Vorontchikhina M, Wang YL, Faiola F, Martinez E. STAGA recruits Mediator to MYC oncoprotein to stimulate transcription and cell proliferation. Mol Cell Biol 2008; 28:108-21.
16. Oishi H, Kitagawa H, Wada O, Takezawa S, Tora L, Kouzu-Fujita M, et al. An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification. J Biol Chem 2006; 281:20-6.
17. Gamper AM, Roeder RG. Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage. Mol Cell Biol 2008; 28:2517-27.
18. Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 2003; 22:6550-61.
19. Grant PA, Duggan L, Cote J, Roberts SM, Brownell JE, Candau R, et al. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an ADA complex and SAGA (Spt/Ada) complex. Genes Dev 1997; 111:640-50.
20. Trievel RC, Rojas JR, Sterner DE, Venkataramani RN, Wang L, Zhou J, et al. Crystal structure and mechanism of histone acetylation of the yeast GCN5 transcriptional coactivator 1999; 96:8931-6.
21. Zhang WZ, Bone JR, Edmondson DG, Turner BM, Roth SY. Essential and redundant functions of histone acetylation revealed by mutation of target lysines and loss of the Gcn5p acetyltransferase. EMBO J 1998; 17:3155-67.
22. Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, et al. Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 2009; 35:352-64.
23. Daniel JA, Torok MS, Sun ZW, Schieltz D, Allis CD, Yates JR, 3rd, Grant PA. Deubiquitination of histone H2B by a yeast acetyltransferase complex regulates transcription. J Biol Chem 2004; 279:1867-71.
24. Vernarecci S, Ornaghi P, Bâgu A, Cundari E, Ballario P, Filetici P. Gcn5p plays an important role in centromere kinetochore function in budding yeast. Mol Cell Biol 2008; 28:988-96.
25. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, et al. Fusion of MOZ and p300 histone acetyltrasferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome traslocation. Leukemia 2001; 15:89-94.
26. Katsumoto T, Yoshida N, Kitabayashi I. Roles of the histone acetyltransferases monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. CancerSci 2008; 99:1523-7.
27. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996; 12:1565-9.
28. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24:300-3.
29. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 2009; 116:225-37.
30. Murata T, Kurokawa R, Krones A, Tatsumi K, Ishii M, Taki T, et al. Defect of histone acetyl-transferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet 2001; 10:1071-6.
31. Rouaux C, Jokic N, Mbebi C, Boutiller S, Loeffler JP, Boutiller AL. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J 2003; 22:6537-49.
32. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9:309-19.
33. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for treatment in cancer. Blood Cells Mol Dis 2001; 27:260-4.
34. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84.
35. Varier RA, Swaminathan V, BAlasubramanyam K, Kundu TK. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol 2004; 68:1215-20.
36. Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK. Polyisoprenylated Benzophenone, Garcinol, a natural histone acetyltrasferase Inhibitor, represses chromatin trascription and alters global gene expression. J Biol Chem 2004; 279:33716-26.
37. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Sidappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein specific inhibitor of acetyltransferase, repress the acetylation of histone/nonhistone preotein and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279:51163-71.
38. Lau OD, Kundu TK, Soccio RE, et al. HATs Off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 2000; 5:589-95.
39. Sagar V, Zheng W, Thomson PR, Cole PA. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg Med Chem 2004; 12:3383-90.
40. Mantelingu K, Reddy BA, Swaminathan V, Kishore AH, Siddappa NB, Kumar GV, et al. Specific inibition of p300-HAT alters gene expression and represses HIV replication. Chem Biol 2007; 645-57.
41. Biel M, Androniki K, Karatzali E, Papamatheakis J, Athanassios G. Design, synthesis and biological evaluation of a small-molecule inhibitor of the histone Acetylatrasferase Gcn5. Angew Chem Int Ed Engl 2004; 43:3974-6.
42. Stimson I, Rowlands MG, Newbatt YM, Smith NF, Raynaud FI, Rogers P, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005; 4:1521-32.
43. Mai A, Rotili D, Tarantino D, Ornaghi P, Tosi F, Vicidomini C, et al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 2006; 49:6897-907.
44. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol 2007; 11:1025-40.
45. Filetici P, Ornaghi P, Ballario P. The bromodomain: a chromatin browser? Front Biosci 2001; 6:866-76.
46. Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P, et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J 2000; 15:6141-9.
47. Morinière J, Rousseaux S, Steuerwald U, Soler-López M, Curtet S, Vitte AL, et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 2009; 46:664-8.
48. Sanchez R, Zhou MM. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel 2009; 12:659-65.
49. Eichenbaum KD, Rodríguez Y, Mezei M, Osman R. The energetics of the acetylation switch in p53-mediated transcriptional activation. Proteins 2010; 78:447-56.
50. Yamada HY, Rao CV. BRD8 is a potential chemosensitizing target for spindle poisons in colorectal cancer therapy. Int J Oncol 2009; 35:1101-9.
51. Menacho-Marquez M, Murgia JR. Yeast on drugs: Saccharomyc cerevisiae as a tool for anticancer drug research. Clin Transl Oncol 2007; 9:221-8.
52. Boone C, Bussey H, Andrews BJ. Exploring genetic interactions and networks with yeast. Nature Rev Genet 2007; 8:437-49.
53. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jaramillo DF, et al. Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc Natl Acad Sci USA 2004; 101:793-8.
54. Pierce SE, Davis RW, Nislow C, Giaever G. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nat Protoc 2007; 2:2958-74.
55. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, Lee W, et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 2008; 320:362-5.
56. Wuster A, Madan Babu M. Chemogenomics and biotechnology. Trends Biotechnol 2008; 5:252-8.
57. Baetz K, McHardy L, Gable K, Tarling T, Rebérioux D, Bryan J, et al. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc Natl Acad Sci USA 2004; 10:4525-30.
58. Manzo F, Tambaro FP, Mai A, Altucci L. Histone acetyltrasferase inhibitors and preclinical studies. Expert Opin Ther Patents 2009; 19:761-74.
59. Mateo F, Vidal-Laliena M, Canela N, Busino L, Martinez-Balbas MA, Pagano M, et al. Degradation of cyclin A is regulated by acetylation. Oncogene 2009; 28:2654-66.
60. Choi E, Choe H, Min J, Choi JY, Kim J, Lee H. BubR1 acetylation at prometaphase is required for modulating APC/C activity and timing of mitosis. EMBO J 2009; 28:2077-89.